IDH-Mutant Myeloid Neoplasms are Associated with Seronegative Rheumatoid Arthritis and Innate Immune Activation

Lih En Hong, Mihir D. Wechalekar, Monika Kutyna, Annabelle Small, Kelly Lim, Chloe Thompson-Peach, Joule J. Li, Rakchha Chhetri, Hamish S. Scott, Anna Brown, Christopher N. Hahn, David T. Yeung, Salvia Sajid, Nirmal Robinson, Ranjeny Thomas, Susan Branford, Richard J. D'Andrea, Saumya E. Samaraweera, Mrinal Patnaik, Susanna ProudmanDaniel Thomas, Chung Hoow Kok, Mithun V. Shah, Devendra K. Hiwase

Research output: Contribution to journalLetterpeer-review

1 Citation (Scopus)
36 Downloads (Pure)

Abstract

High prevalence of IDH mutations in seronegative rheumatoid arthritis (RA) with myeloid neoplasm, elevated 2-hydroxyglutarate, dysregulated innate immunity, and proinflammatory microenvironment suggests causative association between IDH mutations and seronegative RA. Our findings merit investigation of IDH inhibitors as therapeutics for seronegative IDH-mutated RA.

Original languageEnglish
Pages (from-to)1873-1877
Number of pages5
JournalBlood
Volume143
Issue number18
DOIs
Publication statusPublished - 2 May 2024

Bibliographical note

Publisher Copyright:
© 2024 American Society of Hematology

Keywords

  • MDS
  • AIRD
  • t-MN
  • autoimmune rheumatic diseases

Fingerprint

Dive into the research topics of 'IDH-Mutant Myeloid Neoplasms are Associated with Seronegative Rheumatoid Arthritis and Innate Immune Activation'. Together they form a unique fingerprint.

Cite this